The mutual regulation between DNMT3a and Plk1 demonstrated above provides a strong rational to test whether Plk1 inhibition and 5‐Aza can inhibit advanced PCa, such as enzalutamide‐resistant CRPC synergistically. The gene discussed is PLK1; the disease is posterior cortical atrophy.